Hurdles to the Introduction of New Therapies for Immune-mediated Kidney Diseases

Overview

Journal Nat Rev Nephrol

Specialty Nephrology

Date 2016 Jan 26

PMID 26804020

Citations 21

Authors

Hans-Joachim Anders

David R W Jayne

Brad H Rovin

Affiliations

Soon will be listed here.

Abstract

Innovative immunotherapies continue to markedly benefit many disciplines in clinical medicine but disappointingly, these benefits have not translated to the treatment of kidney diseases despite encouraging findings from preclinical models of kidney dysfunction. This lack of progress in nephrology might relate to the unique biology of the kidney. More likely, this lack of progress relates to conceptual hurdles in the application of newer therapies to renal disease. In this Review we discuss seven hurdles that must be addressed in order to appropriately assess and introduce immunologic therapies for immune-mediated kidney disease: the use of appropriate criteria to define disease categories; issues relating to the heterogeneity of kidney diseases and how this heterogeneity affects approaches to treatment; issues related to the rarity of most kidney diseases; the paucity of good animal models of human kidney disease; issues relating to trial design; problems with current approaches to the identification and use of appropriate and feasible study end points; and a lack of adequate biomarkers of intrarenal inflammation and parenchymal injury. We suggest that overcoming these hurdles, in addition to searching for better therapeutic targets, will be necessary to progress the treatment of immune-mediated kidney disease into a new age of drug therapy.

Citing Articles

The current use of proteomics and metabolomics in glomerulonephritis: a systematic literature review.

Davies E, Chetwynd A, McDowell G, Rao A, Oni L J Nephrol. 2024; 37(5):1209-1225.

PMID: 38689160 PMC: 11405440. DOI: 10.1007/s40620-024-01923-w.

The Immunodiagnostic Utility of Antinuclear Antibody Patterns: A Prediction for Renal Involvement in Systemic Lupus Erythematosus Patients in the Western Region of Saudi Arabia.

Al-Mughales J Cureus. 2023; 15(8):e43532.

PMID: 37719585 PMC: 10501496. DOI: 10.7759/cureus.43532.

Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial.

Jayne D, Rovin B, Mysler E, Furie R, Houssiau F, Trasieva T Lupus Sci Med. 2023; 10(2).

PMID: 37607780 PMC: 10445374. DOI: 10.1136/lupus-2023-000910.

Noninvasive Evaluation of Lupus Nephritis Activity Using a Radiomics Machine Learning Model Based on Ultrasound.

Qin X, Xia L, Zhu C, Hu X, Xiao W, Xie X J Inflamm Res. 2023; 16:433-441.

PMID: 36761904 PMC: 9904229. DOI: 10.2147/JIR.S398399.

Glomerulonephritis: immunopathogenesis and immunotherapy.

Anders H, Kitching A, Leung N, Romagnani P Nat Rev Immunol. 2023; 23(7):453-471.

PMID: 36635359 PMC: 9838307. DOI: 10.1038/s41577-022-00816-y.

References

Dooley M, Jayne D, Ginzler E, Isenberg D, Olsen N, Wofsy D . Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011; 365(20):1886-95. DOI: 10.1056/NEJMoa1014460. View

Tamirou F, DCruz D, Sangle S, Remy P, Vasconcelos C, Fiehn C . Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Ann Rheum Dis. 2015; 75(3):526-31. PMC: 4789692. DOI: 10.1136/annrheumdis-2014-206897. View

Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw S, Bell M . Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013; 17(1):R25. PMC: 4057242. DOI: 10.1186/cc12503. View

Mysler E, Spindler A, Guzman R, Bijl M, Jayne D, Furie R . Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum. 2013; 65(9):2368-79. DOI: 10.1002/art.38037. View

Morrish A, Hawley C, Johnson D, Badve S, Perkovic V, Reidlinger D . Establishing a clinical trials network in nephrology: experience of the Australasian Kidney Trials Network. Kidney Int. 2013; 85(1):23-30. PMC: 3898483. DOI: 10.1038/ki.2013.391. View

Weening J, Jennette J . Historical milestones in renal pathology. Virchows Arch. 2012; 461(1):3-11. PMC: 3400763. DOI: 10.1007/s00428-012-1254-7. View

Jansen N, van Oeveren W, van Vliet M, Stoutenbeek C, Eysman L, Wildevuur C . The role of different types of corticosteroids on the inflammatory mediators in cardiopulmonary bypass. Eur J Cardiothorac Surg. 1991; 5(4):211-7. DOI: 10.1016/1010-7940(91)90032-f. View

Parikh S, Ayoub I, Rovin B . The kidney biopsy in lupus nephritis: time to move beyond histology. Nephrol Dial Transplant. 2014; 30(1):3-6. DOI: 10.1093/ndt/gfu348. View

Llovera G, Hofmann K, Roth S, Salas-Perdomo A, Ferrer-Ferrer M, Perego C . Results of a preclinical randomized controlled multicenter trial (pRCT): Anti-CD49d treatment for acute brain ischemia. Sci Transl Med. 2015; 7(299):299ra121. DOI: 10.1126/scitranslmed.aaa9853. View

10.

Risch L, Lhotta K, Meier D, Medina-Escobar P, Nydegger U, Risch M . The serum uromodulin level is associated with kidney function. Clin Chem Lab Med. 2014; 52(12):1755-61. DOI: 10.1515/cclm-2014-0505. View

11.

Hildebrandt F . Genetic kidney diseases. Lancet. 2010; 375(9722):1287-95. PMC: 2898711. DOI: 10.1016/S0140-6736(10)60236-X. View

12.

Reich H, Troyanov S, Scholey J, Cattran D . Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007; 18(12):3177-83. DOI: 10.1681/ASN.2007050526. View

13.

Jayne D, Rasmussen N . Twenty-five years of European Union collaboration in ANCA-associated vasculitis research. Nephrol Dial Transplant. 2015; 30 Suppl 1:i1-7. DOI: 10.1093/ndt/gfv060. View

14.

Trachtman H, Fervenza F, Gipson D, Heering P, Jayne D, Peters H . A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 2011; 79(11):1236-43. PMC: 3257033. DOI: 10.1038/ki.2011.33. View

15.

Hirst J, Howick J, Aronson J, Roberts N, Perera R, Koshiaris C . The need for randomization in animal trials: an overview of systematic reviews. PLoS One. 2014; 9(6):e98856. PMC: 4048216. DOI: 10.1371/journal.pone.0098856. View

16.

Enghard P, Rieder C, Kopetschke K, Klocke J, Undeutsch R, Biesen R . Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. Ann Rheum Dis. 2013; 73(1):277-83. DOI: 10.1136/annrheumdis-2012-202784. View

17.

DallEra M, Stone D, Levesque V, Cisternas M, Wofsy D . Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Arthritis Care Res (Hoboken). 2010; 63(3):351-7. DOI: 10.1002/acr.20397. View

18.

Furie R, Nicholls K, Cheng T, Houssiau F, Burgos-Vargas R, Chen S . Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014; 66(2):379-89. DOI: 10.1002/art.38260. View

19.

Freedman B, Langefeld C, Andringa K, Croker J, Williams A, Garner N . End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 2014; 66(2):390-6. PMC: 4002759. DOI: 10.1002/art.38220. View

20.

DAcquisto F, May M, Ghosh S . Inhibition of nuclear factor kappa B (NF-B): an emerging theme in anti-inflammatory therapies. Mol Interv. 2004; 2(1):22-35. DOI: 10.1124/mi.2.1.22. View